Drugs that block estrogen may lower women's risk of breast cancer for 10 years, according to a new review of studies. Postmenopausal women in the studies who took drugs called selective estrogen receptor modulators (SERMs), such as tamoxifen, were 38 percent less likely to develop any type of breast cancer over a 10-year period, compared with women who werent taking SERMs. The studies also involved the SERMs raloxifene, arzoxifene and lasofoxifene. The review shows that "each of these drugs will prevent breast cancer in populations of women," said Dr. V. Craig Jordan, scientific director of oncology at the Lombardi Comprehensive Cancer Center at Georgetown University. The review "places into perspective the 40-year journey" of SERM research, said Jordan, whose studies in the 1970s showed that tamoxifen prevented mammary cancer in rats. He was not involved in the new study. Only tamoxifen and raloxifene are approved by the Food and Drug Administration for the prevention of breast cancer, and only tamoxifen is approved for use in premenopausal women who are at high risk for breast cancer. The other drugs in the studies are currently being studied as treatments for osteoporosis, but they also lower the risk of breast cancer, Jordan said. … Continue reading →

NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Ophthalmic Drugs: World Market Prospects 2013-2023 http://www.reportlinker.com/p0847305/Ophthalmic-Drugs-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Report Details How to find trends and revenue predictions for the ophthalmic drug industry What are the commercial prospects for treating eye disorders? Visiongain's new report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for ocular drugs. Our study lets you assess sales data at overall world market, submarket and national level. There you find that industry's most promising and lucrative segments, helping your research and analyses. Therapies for treating eye disorders and diseases have rising demand. See the future of ophthalmic medicines and discover how sales of ocular drugs can increase. Forecasts and other analyses to help you stay ahead in knowledge In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (inc. SWOT), business outlooks and research and development (R&D). You receive 48 tables, 74 charts and 9 interviews. Read more: Ophthalmic Drugs: World Market Prospects 2013-2023 … Continue reading →

NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Dermatological Drugs: World Market Prospects 2013-2023 http://www.reportlinker.com/p0788690/Dermatological-Drugs-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Report Details Your guide to revenue prospects for the treatment of skin diseases What's the commercial outlook for treating skin disorders? Visiongain's updated report gives you forecasted revenues to 2023 and also explains R&D trends, outlooks and opportunities. Our study lets you assess sales data for the world market, therapeutic submarkets, products and national markets. It shows you that industry's most promising and lucrative segments. Forecasts and other analyses to help you stay ahead in knowledge The report gives you revenue forecasts to 2023, historical data, growth rates and market shares. Also, it lets you see qualitative analysis (SWOT and STEP), business outlooks and developmental trends (R&D). You gain 99 tables, 61 charts and two research interviews. Is finding commercial details a challenge? Our report helps you get ahead in knowledge, benefiting your research, analyses and decisions. Find trends, innovations and opportunities. You see what's happening. There's rising demand for dermal medicines. Discover areas of the market that will prosper, reducing the risk of your being left behind. Read more: Dermatological Drugs: World … Continue reading →

NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Antibacterial Drugs: World Market Prospects 2013-2023 http://www.reportlinker.com/p0739371/Antibacterial-Drugs-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Report Details Discover new trends, opportunities and revenue prospects for bacteria-killing medicines Where's the antibiotics market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities. Our study lets you assess sales data and predictions for the world antibacterial drugs market, therapeutic submarkets, important products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments. Established and emerging bacteria-treating technologies have potential. Read on to scan features of that industry, find what drives it, and see what its future market could be worth. Forecasts and other analyses to help you stay ahead in knowledge That report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developmental trends (R&D). You gain 113 tables, 86 charts and two research interviews. Is finding commercial data a challenge? With our study you can stay ahead in knowledge, benefiting your research, analyses and … Continue reading →